Opiant Pharmaceuticals (OPNT) Posts Wider Q1 Loss
Tweet
Share
E-mailGet Alerts OPNT Hot Sheet
Price: $20.65 --0%
Financial Fact:
Research and development: 10.99M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Financial Fact:
Research and development: 10.99M
Today's EPS Names:
OTLK, EGRX, MOVE, More
Join SI Premium – FREE
Opiant Pharmaceuticals (NASDAQ: OPNT) reported Q1 EPS of ($2.43), $1.52 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $4.5 million versus the consensus estimate of $5.9 million.
For earnings history and earnings-related data on Opiant Pharmaceuticals (OPNT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fox upgraded to overweight as Roku deal, ad strength lift outlook
- Workhorse Group (WKHS) Misses Q2 EPS by 77c
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
